Logotype for Journey Medical Corp

Journey Medical (DERM) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Journey Medical Corp

Q3 2026 earnings summary

12 Nov, 2026

Executive summary

  • Q3 revenue rose 8% YoY to $19.0M; Emrosi revenue grew 84% to $9.0M, and adjusted EBITDA was positive for a second consecutive quarter.

  • 9M revenue increased 17% to $53.4M, while net loss narrowed to $3.9M from $10.2M.

  • Emrosi demand, refill trends, prescriber growth and improving payer reimbursement mix supported momentum.

Financial highlights

  • Q3 product revenue was $18.9M, up 11% YoY; other revenue fell 93% to $42K as prior-year Cutia supply revenue did not recur.

  • Q3 GAAP net loss narrowed to $1.315M, or $0.05/share, from $2.315M, or $0.09/share; operating loss narrowed to $530K from $1.5M.

  • Gross margin was 69% versus 67% in Q3 2025, primarily reflecting Emrosi’s lower cost impact on cost of sales.

  • SG&A was $12.6M, up $0.5M YoY; it included a one-time $1.7M former-vendor settlement, partly offset by lower Emrosi launch costs.

  • Cash was $22.3M at Sept. 30, 2026, versus $24.1M at Dec. 31, 2025; working capital was $25.7M versus $29.4M.

Outlook and guidance

  • A national plan covering over 25M lives is expected to add Emrosi to its formulary in January 2027, with impact expected to begin in Q1.

  • Management expects ASP to rise and gross-to-net to improve as formulary wins flow through in 2027; Q1 deductible resets may delay the benefit.

  • Management is considering 2027 guidance and expects caution in H1 while assessing patient mix, formulary adoption and stabilization; SG&A as a share of revenue is expected to remain steady or decrease slightly.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Journey Medical